The effects of central administration of neuropeptide Y on behavior of tenascin-gene knockout mice

Neuropeptides

Volumn 32, Issue 5, 1998, Pages 461-464

  Fukamauchi, F ^a   Aihara, O ^a   Kusakabe, M ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN TSUKUBA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ARTICLE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GROWTH REGULATION; KNOCKOUT MOUSE; LIMBIC CORTEX; LOCOMOTION; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION;

ANIMALIA;

EID: 0031738295     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(98)90072-5     Document Type: Article

References (20)

1. Bartsch S, Bartsch U, Dorries U et al. Expression of tenascin in the developing and adult cerebellar cortex. J Neurosci 1992; 12: 736-749.
2. Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 1993; 5: 869-876.
3. Erickson HP, Bourdon MA. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Ann Rev Cell Biol 1989; 5: 71-92.
4. Laywell E, Dorries U, Bartsch U, Faissner A, Schachner M, Steindler DA. Enhanced expression of the developmentally regulated extracellular matrix molecule tenascin following adult brain injury. Proc Natl Acad Sci USA 1992; 89: 2634-2638.
5. Chiquet-Ehrismann R, Hagios C, Matsumoto KI. The tenascin gene family. Perspect Dev Neurobiol 1994; 2: 3-7.
6. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992; 6: 1821-1831.
7. Fukamauchi F, Mataga N, Wang YJ, Sato S, Yoshiki A, Kusakabe M. Abnormal behavior and neurotransmissions of tenascin gene knockout mouse. Biochem Biophys Res Commun 1996; 221: 151-156.
8. Grundemar L, Hakanson R. Neuropeptide Y effector systems: perspectives for drug development. Trend Pharmacol Sci 1994; 15: 153-159.
9. Heilig M, Widerlov E. Neurobiology and clinical aspects of neuropeptide Y. Critical Reviews in Neurobiology 1995; 9: 115-136.
10. Wettstein JG, Earley B, Junien JL. Central nervous system pharmacology of neuropeptide Y. Pharmacology and Therapeutics 1995; 65: 397-414.
11. Kunovac JL, Stahl SM. Future directions in anxiolytic pharmacology. Psychiatric Clinics of North America 1995; 18: 895-909.
12. Fukamauchi F, Aihara O, Kusakabe M. Reduced mRNA expression of neuropeptide Y in the limbic system of tenascingene disrupted mouse brain. Neuropeptides 1998; 32.
13. Fukamauchia F, Wang YJ, Mataga N, Kusakabe M. Paradoxical behavioral response to apomorphine in tenascin-gene knockout mouse. Eur J Pharmacol 1997; 338: 7-10.
14. Crawley JN. Neuropharmacologic specificity of a simple animmal model for the behavioral actions of benzodiazepines. Pharmac Biochem Behav 1981; 15: 695-699.
15. Vasar E, Harro J, Pold A, Lang A. CCK receptors and anxiety in rats. Oxford: CT Dourish, SJ Cooper, SD Iversen, LL Iversen. 1992: 143.
16. Heilig M, Koob GF, Ekman R, Britton KT. Corticotropinreleasing factor and neuropeptide Y: role in emotional integration. Trend Neurosci 1994; 17: 80-85.
17. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Yl receptors by antisense of oligodeoxynucleotides. Science 1993; 259: 528-531.
18. Bendotti C, Tarizzo G, Fumagalli F, Baldessari S, Samanin R. Increased expression of preproneuropeptide Y and preprosomatostatin mRNA in striatum after selective serotonergic lesions in rats. Neurosci Lett 1993; 160: 197-200,
19. Currie PJ, Coscina DV. Stimulation of 5HT2A/2C receptors within specific hypothalamic nuclei differentially antagonizes NPY-induced feeding. NeuroReport 1997; 8: 3759-3762.
20. Smialowska M. An inhibitory dopaminergic regulation of the neuropeptide Y immunoreactivity expression in the rat cerebral cortex neuron. Neuroscience 1995; 66: 589-595.